SENS.L Regulatory News (SENS)

Board Change

Oxford, U.K. 02 August 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the ethical Clinical AI company, today announces that Dr Vishal Gulati is stepping down from the Board of directors effective from 30 July 2021 to focus on other business opportunities. Dr Gulati will continue to act as an adviser to the Company on a part-time basis.

Sir Bruce Keogh, Chairman of Sensyne Health commented: "Vishal has been a key member of the Board for several years and has played a pivotal role in guiding Sensyne through its transition from a private into a publicly listed company on the London Stock Exchange. His expertise and counsel have been important to Sensyne's subsequent growth. On behalf of the Board, I would like to thank Vishal for his support and guidance and look forward to his continuing contribution towards the future success of the business in his advisory role."

The Sensyne Health Board further to Dr Gulati's departure will be as follows:

Sir Bruce Keogh, Non-Executive Chairman

Lord Paul Drayson, Chief Executive Officer

Dr. Richard Pye, Chief Financial Officer

Tony Bourne, Independent Non-Executive Director

Dr. Ian Hudson, Independent Non-Executive Director

Michael Norris, Independent Non-Executive Director

Geoff Race, Independent Non-Executive Director

Mary Hardy, Senior Independent Director

Professor Lionel Tarassenko, Non-Executive Director

About Sensyne Health: https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

For more information please contact: